Eduovisual
Emergency & Toxicology
Lead poisoning: children and adults, chelation thresholds
— Lead inhibits δ-aminolevulinic acid dehydratase (ALAD) and ferrochelatase, blocking heme synthesis → microcytic anemia, elevated erythrocyte protoporphyrin (EP/ZPP), and elevated urinary ALA.
— Mimics calcium → neuronal apoptosis, impaired NMDA signaling, hypertension, nephrotoxicity.
— Stored in bone (>90%) with half-life of decades; remobilized in pregnancy, lactation, hyperthyroidism, immobilization.
— Pre-1978 housing with peeling paint, lead pipes, recent renovation, imported toys/cosmetics (kohl, surma), pottery glazes, folk remedies (azarcón, greta), parental occupation (battery, smelter, demolition, firing range).
— Pica, developmental delay, unexplained microcytic anemia, behavior/attention problems, abdominal pain, constipation.
— USPSTF: insufficient evidence for universal screening of asymptomatic children, but CMS/Medicaid mandates BLL at 12 and 24 months for all enrolled children, plus targeted screening per state/local risk maps.
— Occupational: battery manufacturing/recycling, radiator repair, lead smelting, construction/demolition, indoor firing range instructors, stained-glass artisans.
— Hobbyist: bullet casting, ceramics, antique restoration.
— Retained bullet/shrapnel in joint space or near bone.
— Moonshine ingestion ("saturnine gout"), Ayurvedic supplements.
— Symptoms: fatigue, HTN, abdominal colic, peripheral neuropathy, infertility, cognitive decline, gout flares.
Board pearl: OSHA action level for occupational exposure is BLL ≥40 µg/dL with mandatory medical removal at ≥50 µg/dL (construction) or ≥60 µg/dL (general industry) — these are surveillance thresholds, not chelation thresholds. Always anchor exam answers to the specific BLL trigger the question is testing.
— <10 µg/dL: Usually asymptomatic; subclinical IQ loss, attention/behavior issues, decreased academic performance.
— 10–44 µg/dL: Irritability, decreased play, anorexia, sporadic abdominal pain, mild developmental regression.
— 45–69 µg/dL: Abdominal colic, constipation, vomiting, anemia, lethargy.
— ≥70 µg/dL: Lead encephalopathy — ataxia, seizures, altered mental status, coma, papilledema, cerebral edema. Medical emergency.
— <40 µg/dL: Often asymptomatic or fatigue, mood symptoms, mild HTN.
— 40–80 µg/dL: Abdominal "lead colic" (diffuse, crampy, no peritoneal signs), arthralgias, headache, decreased libido, oligospermia, hypertension, gouty attacks ("saturnine gout" — lead-induced urate retention).
— >80–100 µg/dL: Wrist/foot drop (motor predominant peripheral neuropathy, classically radial nerve), nephropathy, encephalopathy.
— Age of home (pre-1978 US housing = lead paint risk), recent renovation/sanding, well water, lead service lines (Flint-style exposures).
— Caregiver occupation/hobby — lead dust tracked home on clothing is a tested exam stem.
— Imported foods, spices (turmeric adulteration), candy wrappers, cosmetics, ceramic dishware, herbal/Ayurvedic medications.
— Pica behavior, developmental milestones, school performance.
— In adults: refractory hypertension, gout in young patient, infertility workup.
Key distinction: Lead colic mimics surgical abdomen but lacks peritoneal signs, fever, leukocytosis, or imaging abnormalities — an unnecessary laparotomy is the classic miss. Always ask about occupation/hobbies in a young adult with recurrent unexplained abdominal pain plus HTN, anemia, or gout. The combination abdominal pain + microcytic anemia + wrist drop + gingival lead lines is pathognomonic on boards but rare in practice.
— Burton's line — bluish-black gingival pigmentation at the tooth-gum margin from lead sulfide deposition; seen with chronic high-level exposure and poor oral hygiene. Rare today but a board favorite.
— Pallor (anemia), poor growth in children, mild hepatomegaly uncommon.
— Papilledema if encephalopathy — examine fundi in any child with elevated BLL and AMS.
— Decreased developmental milestones, hypotonia, irritability.
— Encephalopathy: lethargy, ataxia, seizures (often focal), bulging fontanelle in infants, signs of increased ICP.
— Document baseline mental status and growth parameters for longitudinal monitoring.
— Peripheral motor neuropathy — classically wrist drop (radial nerve) and foot drop (peroneal); extensor weakness > flexor, sensation relatively preserved.
— Decreased deep tendon reflexes in affected limb.
— Subtle cognitive slowing, memory deficits, mood lability.
— Hypertension — lead is an under-recognized cause of resistant or early-onset HTN.
— Signs of CKD in long-term exposure: peripheral edema, uremic features in advanced disease.
— Diffuse abdominal tenderness without rebound or guarding ("lead colic").
— Gouty tophi or acute monoarthritis in saturnine gout.
— Children: imaging may show "lead lines" — dense metaphyseal bands at growth plates on long-bone X-rays (not the same as Burton's gingival line).
Step 3 management: A child with BLL ≥45 µg/dL or any symptomatic child needs a focused neuro exam plus abdominal X-ray to detect radiopaque paint chips/foreign bodies — if positive, perform whole-bowel irrigation with polyethylene glycol before initiating chelation, because chelating an unevacuated gut load can paradoxically increase absorption. Document a pre-chelation neuro baseline.
— Capillary (fingerstick) BLL is acceptable for screening only; any elevated capillary result must be confirmed by venous sample before management decisions.
— Confirmation timing per CDC:
– Capillary 3.5–9 µg/dL → venous within 1–3 months
– 10–44 µg/dL → within 1 week–1 month
– 45–59 µg/dL → within 48 hours
– 60–69 µg/dL → within 24 hours
– ≥70 µg/dL → immediately, treat as emergency
— Microcytic, hypochromic anemia (mimics iron deficiency) — often coexistent because iron deficiency increases lead absorption via DMT1 transporter.
— Basophilic stippling of erythrocytes — coarse blue granules from inhibited pyrimidine 5′-nucleotidase; classic but not specific (also in thalassemia, sideroblastic anemia).
Board pearl: A child with microcytic anemia + basophilic stippling + low-normal ferritin plus pre-1978 housing → check BLL before iterating iron studies. Key distinction: ZPP/EP reflects chronic burden; venous BLL reflects recent + current burden — both can be useful but BLL drives chelation decisions.
— Standard BLL reflects ~1-month exposure (RBC half-life).
— K-shell X-ray fluorescence (KXRF) measures cortical bone lead, the long-term body burden reservoir — used in research/occupational medicine, especially when evaluating pregnancy-related remobilization or chronic CKD/HTN of suspected lead origin.
— Long-bone radiographs (knees, wrists) in children — transverse metaphyseal "lead lines" indicate chronic exposure during growth; absent lines do not exclude poisoning.
— Abdominal radiograph — radiopaque paint chips, fishing sinkers, ingested jewelry (a swallowed metallic charm is a classic exam stem for an acutely toxic child).
— Head CT/MRI if encephalopathy — diffuse cerebral edema, posterior reversible patterns; rule out other causes of AMS.
— Report any confirmed elevated pediatric BLL to local/state health department — they perform home environmental inspection (paint, dust, soil, water).
— In adults, refer to OSHA-regulated medical surveillance if occupational; obtain workplace air-lead sampling.
Step 3 management: For a child with confirmed BLL ≥5 µg/dL, the next systems-level steps are (1) report to public health, (2) home risk assessment/abatement, (3) test siblings and playmates in the same household, and (4) screen for iron, calcium, vitamin C, and zinc deficiencies — all of which increase lead absorption. The exam often rewards the environmental/public-health answer over additional lab testing.
— <3.5 µg/dL: Routine anticipatory guidance; recheck per age-based schedule.
— 3.5–19 µg/dL: Confirm venous, environmental investigation, nutritional counseling (iron, calcium, vit C), retest in 1–3 months, then every 3 months until declining. No chelation.
— 20–44 µg/dL: As above plus comprehensive medical evaluation, abdominal x-ray if pica, neurodevelopmental assessment. Chelation generally not indicated in this range alone.
— 45–69 µg/dL (asymptomatic): Oral chelation with succimer (DMSA). Hospitalize only if home is not lead-safe.
— ≥70 µg/dL or symptomatic/encephalopathy at any level: Hospitalize, ICU if encephalopathy, dual parenteral chelation with dimercaprol (BAL) + CaNa₂EDTA.
— <10 µg/dL: No specific action; identify source.
— 10–24 µg/dL: Remove from exposure if occupational, recheck monthly.
— 25–39 µg/dL: OSHA documentation; counsel exposure reduction; no chelation.
— 40–79 µg/dL: Removal from workplace required if occupational; chelation only if symptomatic.
— ≥80 µg/dL or symptomatic at lower level: Chelate — oral DMSA for stable patients; BAL + EDTA for encephalopathy or BLL >100.
— Confirm exposure is interrupted — never chelate a patient returning to a leaded environment; mobilized lead redistributes and worsens toxicity.
— Evacuate GI lead burden before systemic chelation.
— Correct iron deficiency concurrently.
CCS pearl: On CCS, ordering "chelation" without first "remove from exposure," "abdominal x-ray," "whole-bowel irrigation if positive," and "admit" loses points. Sequence: source → gut → chelator. Reassess BLL 7–21 days post-chelation to detect rebound from bone redistribution.
— Oral, water-soluble dimercaprol analog.
— Indication: Children with BLL 45–69 µg/dL asymptomatic; adults symptomatic with BLL 70–100 without encephalopathy.
— Dose: 10 mg/kg PO q8h × 5 days, then q12h × 14 days (19-day course).
— Adverse effects: GI upset, transaminitis (monitor LFTs), rash, neutropenia (check CBC), metallic taste.
— Safe outpatient if lead-safe home confirmed; well tolerated.
— Parenteral (IV continuous infusion or deep IM); not Na₂EDTA — that formulation causes fatal hypocalcemia and is contraindicated.
— Indication: BLL ≥70 µg/dL, encephalopathy (combined with BAL), or symptomatic.
— Dose: 1000–1500 mg/m²/day IV × 5 days.
— Adverse effects: Nephrotoxicity (hydrate, monitor Cr/UA), zinc depletion, infusion pain. Reduce dose in renal impairment.
— Never give before BAL in encephalopathy — EDTA alone can mobilize lead into the CNS and worsen encephalopathy.
— Deep IM only in peanut oil — contraindicated in peanut allergy and G6PD deficiency.
— Indication: Lead encephalopathy or BLL >70 µg/dL with symptoms; give 4 hours before CaNa₂EDTA.
— Dose: 75 mg/m² IM q4h × 5 days.
— Adverse effects: Hypertension, tachycardia, fever, hemolysis (G6PD), painful injections, nephrotoxicity in acidic urine — alkalinize urine.
— Avoid concurrent iron supplementation — BAL-iron complex is toxic.
Board pearl: The classic stem — child with seizures, BLL 95 µg/dL — answer is BAL first, then EDTA 4 hours later, both for full 5-day course. Never EDTA alone in encephalopathy. Key distinction: DMSA = oral, outpatient-friendly, kids 45–69; BAL+EDTA = parenteral, ICU, encephalopathy or ≥70.
— Move child/family from contaminated dwelling during abatement; HUD-certified lead inspectors required.
— Wet-mop hard floors, HEPA-vacuum carpets; dry sweeping aerosolizes lead dust.
— Remove worker from job site (OSHA medical removal protection: full pay/benefits maintained until BLL falls below return threshold).
— Whole-bowel irrigation with polyethylene glycol electrolyte solution (e.g., GoLYTELY) 25–40 mL/kg/hr until rectal effluent is clear and KUB shows no residual radiopaque material.
— Endoscopic or surgical retrieval if foreign body lodged (e.g., lead-containing bezoar, retained ammunition near joint synovium causing systemic absorption).
— Activated charcoal does NOT bind lead — not useful.
— Iron repletion (lead and iron share DMT1 transporter; deficiency → increased absorption).
— Calcium and vitamin D adequacy reduces GI lead uptake.
— Vitamin C and zinc sufficiency support enzyme function.
— Avoid fasting states; feed frequent meals (empty stomach increases lead absorption 5-fold).
— ICU admission, airway protection, seizure control (benzodiazepines first-line; avoid phenytoin's marginal efficacy here, use levetiracetam).
— Manage cerebral edema: head of bed elevation, hyperosmolar therapy; avoid overhydration which worsens edema, but avoid dehydration which worsens nephrotoxicity — euvolemic strategy.
— Treat hypertension; correct electrolyte derangements.
— Intra-articular/intradiscal lead → surgical removal; soft-tissue fragments encapsulated rarely cause systemic toxicity unless disturbed.
CCS pearl: Sequence on the case is: stabilize ABCs → labs (BLL, CBC, BMP, LFT, UA, KUB) → whole-bowel irrigation if positive → BAL → EDTA 4 hr later → consult toxicology and public health → social work for housing → schedule retest day 7–10 post-chelation.
— Bone is a long-term lead reservoir; osteoporosis, immobilization, hyperparathyroidism, and hyperthyroidism mobilize stored lead decades after exposure — explaining late-onset HTN, CKD, gout, and cognitive decline in retired workers (battery plants, painting, plumbing trades pre-1980).
— Consider lead etiology in unexplained progressive CKD with normal-sized kidneys, hyperuricemia, and HTN ("chronic lead nephropathy") — often diagnosed by occupational history plus KXRF bone lead if available.
— Lower threshold to investigate; symptoms may be attributed to "normal aging."
— Lead worsens CKD and is excreted renally — a vicious cycle.
— CaNa₂EDTA dose reduction required for CrCl <50; avoid if anuric (consider hemodialysis-adjusted dosing in consultation with toxicology).
— DMSA also requires dose adjustment; monitor LFTs and renal function closely.
— Hemodialysis does not effectively remove lead alone, but EDTA + HD can be used in severe toxicity with renal failure — chelator binds lead, HD removes the complex.
— DMSA: hepatic metabolism; check baseline and weekly LFTs; hold if AST/ALT >3× ULN.
— BAL: hepatic concerns less prominent but can cause transaminitis.
— Avoid hepatotoxic co-medications during chelation.
— BAL is contraindicated — risk of hemolysis. Use DMSA or EDTA alternatives; consult toxicology.
Step 3 management: An elderly patient with progressive CKD, refractory HTN, and a history of 30 years as a radiator repairman → check BLL and consider bone-lead testing; even "normal" current BLL doesn't exclude past exposure as the etiology. Smoking cessation, BP control with ACE-I/ARB, and gout prophylaxis are still mainstays — chelation is not indicated for chronic low-level adult lead burden without active symptoms or BLL ≥80.
— Lead crosses placenta freely; fetal BLL ≈ maternal BLL.
— Bone lead mobilizes during pregnancy (increased calcium turnover) → endogenous fetal exposure even without ongoing environmental exposure.
— Outcomes: spontaneous abortion, preterm birth, low birth weight, neurodevelopmental impairment, gestational HTN.
— CDC/ACOG screening: Risk-based — screen pregnant women with occupational exposure, recent immigration from high-lead regions, pica (especially soil/clay/pottery), home renovation, or use of imported cosmetics/remedies.
— Management thresholds:
– BLL <5 µg/dL: routine.
– 5–14 µg/dL: counsel, identify source, recheck.
– 15–44 µg/dL: remove exposure, calcium supplementation (1200–1500 mg/day) to suppress bone resorption, serial BLL.
– ≥45 µg/dL: consult maternal-fetal medicine and toxicology; chelation considered despite teratogenicity concerns because severe maternal toxicity outweighs fetal drug risk. DMSA or CaNa₂EDTA preferred; avoid BAL in first trimester unless encephalopathy.
— Lead transfers to breast milk; for maternal BLL <40 µg/dL, breastfeeding generally encouraged (benefits outweigh risk).
— BLL ≥40 µg/dL: pump and discard until BLL <40, then resume.
— Infants/toddlers absorb 40–50% of ingested lead vs ~10% in adults; developing BBB allows greater CNS penetration.
— Pica peaks at 1–3 years — coincides with mandatory CMS screening at 12 and 24 months.
— Hand-to-mouth behavior + lead dust on floors = primary pediatric exposure route, not paint chip ingestion as commonly assumed.
Board pearl: A pregnant immigrant woman from Mexico with pica for clay pots or "chapulines" (grasshoppers) or using azarcón/greta folk remedies is a classic stem — screen BLL. Key distinction: Maternal calcium supplementation in pregnancy is not just for bone health — it actively suppresses lead mobilization from maternal skeleton, protecting the fetus.
— Permanent IQ deficit — for every 10 µg/dL rise in BLL, estimated 4–7 point IQ loss; effect is greatest at lower BLL ranges (non-linear dose-response — the first 1–10 µg/dL causes proportionally the most harm).
— Attention-deficit/hyperactivity, executive function deficits, conduct disorder, decreased academic achievement.
— Encephalopathy sequelae: seizure disorder, cerebral palsy, intellectual disability, optic atrophy.
— Adult peripheral neuropathy may persist after exposure cessation.
— Microcytic anemia (combined heme synthesis block + hemolysis).
— Basophilic stippling persists weeks after exposure ends.
— Acute: proximal tubular dysfunction (Fanconi syndrome — aminoaciduria, glycosuria, phosphaturia) — usually reversible.
— Chronic: interstitial nephritis → CKD with hyperuricemia and HTN; irreversible.
— Hypertension (even at BLL 5–10 µg/dL in adults).
— Increased cardiovascular mortality at chronic low-level exposure.
— Possible association with coronary disease and stroke.
— Men: decreased sperm count/motility, abnormal morphology, infertility.
— Women: spontaneous abortion, preterm birth, fetal lead burden, lactational transfer.
— EDTA nephrotoxicity, zinc depletion.
— BAL: HTN crises, fever, hemolysis (G6PD), sterile abscess.
— DMSA: transaminitis, neutropenia, rash.
— Rebound BLL elevation from bone remobilization 1–4 weeks post-chelation — schedule retest.
Board pearl: A child treated with chelation whose BLL drops appropriately but rises back to 80% of pre-treatment value 2 weeks later is showing bone-lead redistribution, not failed chelation or re-exposure — counsel families and plan repeat courses if persistently ≥45 µg/dL. The neurocognitive damage already incurred is not reversed by chelation; chelation prevents further injury.
— Any patient with lead encephalopathy (AMS, seizures, ataxia, papilledema).
— BLL ≥70 µg/dL in children regardless of symptoms.
— BLL ≥100 µg/dL in adults.
— Hemodynamic instability, status epilepticus, acute kidney injury requiring close monitoring during chelation.
— Any chelation candidate.
— Diagnostic uncertainty, atypical presentation, mixed exposures.
— Pediatric BLL ≥45 µg/dL or adult ≥80 µg/dL.
— Pregnancy with elevated BLL.
— BLL ≥45 µg/dL in child if home not yet certified lead-safe (cannot discharge to ongoing exposure).
— Symptomatic patients at any BLL.
— Inability of caregivers to administer oral chelation reliably.
— Concurrent foreign body requiring procedural removal.
— Public health/health department — mandatory reporting of elevated pediatric BLL in all US states; triggers home inspection and case management.
— Pediatric neurology/development for any child with BLL ≥20 µg/dL — neurodevelopmental assessment.
— Nephrology for CKD or Fanconi syndrome.
— Occupational medicine for adult workplace exposure; coordinates OSHA-mandated removal.
— Social work — housing instability, abatement coordination, WIC enrollment.
— GI/Surgery for retained foreign body.
CCS pearl: On a CCS case with an encephalopathic child, early orders are: ICU bed, IV access, finger-stick glucose, BLL (venous), CBC/BMP/LFT/UA, KUB, head CT, IV fluids (maintenance, not aggressive), levetiracetam if seizing, BAL IM, then EDTA IV 4 hr later, toxicology consult, public health report, social work — all within the first simulated hour.
— Arsenic: GI distress, garlic breath, Mees' lines on nails, sensory > motor neuropathy (lead is motor > sensory), pancytopenia, hyperpigmentation. Treat with DMSA or BAL. Source: contaminated well water, pesticides, folk remedies.
— Mercury: Tremor, erethism (personality change, irritability), gingivostomatitis, acrodynia in kids (painful pink hands/feet). Inorganic vs organic distinctions matter. Treat with DMSA (inorganic) or supportive care (organic methylmercury — chelation less effective).
— Cadmium: Renal tubular dysfunction, osteomalacia (Itai-Itai), lung injury (inhalation). No effective chelator; supportive care.
— Thallium: Alopecia, painful ascending neuropathy, GI symptoms. Treat with Prussian blue.
— Iron deficiency anemia: low ferritin, high RDW, no basophilic stippling. Often coexists with lead — check BLL in any toddler with IDA, particularly with risk factors.
— Thalassemia minor: elevated HbA₂ (β-thal), target cells, family history, normal ferritin, basophilic stippling can occur — but no lead exposure history.
— Sideroblastic anemia: ring sideroblasts on marrow; can be hereditary (X-linked ALAS2), drug-induced (isoniazid, chloramphenicol), or alcohol-related.
— Anemia of chronic disease: elevated ferritin, low TIBC.
— Pyrimidine 5′-nucleotidase deficiency (hereditary).
— Thalassemias, megaloblastic anemia, myelodysplastic syndrome.
— Mimics lead colic (abdominal pain, neuropathy, neuropsychiatric symptoms) because both inhibit heme synthesis.
— Urine PBG elevated in AIP; BLL normal. Lead inhibits ALAD, AIP has deficient PBG deaminase — both can elevate urine ALA.
Key distinction: Lead = motor neuropathy + microcytic anemia + abdominal colic + basophilic stippling, AIP = sensory + motor neuropathy + abdominal pain WITHOUT anemia + photosensitivity in variants. Always check BLL and urine PBG when porphyria is on the differential.
— Constipation, intussusception, appendicitis, mesenteric adenitis, Henoch-Schönlein purpura, sickle cell crisis, DKA.
— Lead colic lacks fever, peritoneal signs, leukocytosis, or imaging abnormality — but ALWAYS rule out surgical abdomen first if presentation is acute.
— Meningitis/encephalitis — check LP if AMS without clear lead diagnosis.
— Hypoglycemia, DKA, hyponatremia, inborn errors of metabolism (especially infants), nonaccidental trauma with elevated ICP.
— Status epilepticus from any cause.
— Posterior reversible encephalopathy syndrome (PRES).
— Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's, OSA, NSAID/decongestant use, CKD of other etiology — consider lead in patients with relevant occupational/environmental history.
— Diabetes, alcohol, B12 deficiency, chemotherapy (vincristine, platinums), HIV, Guillain-Barré, CIDP, hereditary motor-sensory neuropathy, vasculitis.
— Lead's motor predominance with wrist drop is distinctive but uncommon today.
— Autism spectrum, ADHD, fragile X, fetal alcohol spectrum, hearing/vision loss, parental neglect, generalized anxiety — but always include BLL screen in the differential, especially with environmental risk factors.
— Lead, thalassemia trait, sideroblastic anemia, copper deficiency (rare, often post-bariatric in adults).
Step 3 management: A 3-year-old with new-onset seizures, no fever, normal glucose, lives in a 1920s row house being renovated → BLL is part of the initial workup along with electrolytes, glucose, calcium, head CT, and LP. Don't anchor on febrile seizure or idiopathic epilepsy without considering environmental toxins, particularly carbon monoxide and lead, in the home.
— Federal lead paint ban: residential paint 1978; gasoline phase-out completed 1996.
— Safe Drinking Water Act, Lead and Copper Rule (action level 15 ppb in tap water — note: no safe level).
— HUD lead-safe housing certification.
— Title X disclosure law: sellers/landlords must disclose known lead paint in pre-1978 housing.
— Source elimination first — lead-safe abatement (not "renovation"; untrained removal can worsen exposure by aerosolizing dust). Use EPA-certified Lead Renovation, Repair, and Painting (RRP) contractors.
— Wet-cleaning protocols, frequent handwashing (especially before meals), shoe removal at entry.
— Replace lead water service lines; flush taps for 30 sec before use, cold water only for drinking/cooking.
— Cover bare soil in yards with grass, mulch, or pavers.
— Iron-rich diet + supplementation if deficient.
— Calcium 1000 mg/day (children), 1200–1500 (pregnant/lactating).
— Vitamin C and zinc adequacy.
— Frequent meals; fasting increases lead absorption.
— No maintenance chelation — chelators are pulse courses only.
— Iron, calcium, vitamin D supplementation as indicated.
— Anti-hypertensives in adults with lead-related HTN (ACE-I/ARB preferred for renal protection).
— Anticonvulsants if post-encephalopathic seizure disorder.
— OSHA mandates removal until BLL <40 µg/dL × 2 (general industry) or <40 (construction) over 6 months; full pay/seniority preserved during medical removal protection.
Board pearl: "Lead-safe" ≠ "lead-free." Encapsulating intact paint with EPA-approved sealants is acceptable; the danger is deteriorating paint or sanding/scraping without containment. Recommend professional abatement before family returns to a previously contaminated home.
— 3.5–9 µg/dL: Recheck every 3 months until two consecutive declining values, then every 6–9 months until age 6.
— 10–19 µg/dL: Every 1–3 months until declining, then every 3 months.
— 20–44 µg/dL: Every 2 weeks–1 month initially, then every 1–3 months.
— 45–69 µg/dL: 1 week after chelation, then every 2–4 weeks during the first 6 months; expect rebound and possible repeat course.
— ≥70 µg/dL: Daily during inpatient chelation; weekly for 4 weeks; then per ≥45 schedule.
— OSHA-regulated industries: BLL and ZPP every 6 months (every 2 months if BLL ≥40).
— Symptomatic adults post-chelation: BLL at 1, 4, and 12 weeks.
— Refer all children with BLL ≥20 µg/dL (some say ≥5) to early intervention, developmental pediatrics, or school-based services.
— Annual academic/behavioral monitoring through school age — IEP eligibility may apply.
— Annual BMP, urinalysis, BP for life if prior significant exposure.
— Gout management with allopurinol; avoid uricosurics (probenecid less effective in lead nephropathy).
— Source-specific guidance (renovation, occupation, hobbies, water, imported products).
— Hand hygiene before meals, no eating in work areas, shower/change clothes before coming home (for occupationally exposed).
— Pregnancy planning for women with bone lead burden — calcium repletion preconception.
Step 3 management: Document the public health report, environmental investigation status, sibling screening results, and developmental referral in your discharge summary — these are quality measures and tested transition-of-care points. Coordinate with the PCP; many BLL retests are missed at handoff.
— All US states require reporting of elevated pediatric BLL to local/state health departments — threshold varies (commonly ≥3.5 or ≥5 µg/dL). The clinician's duty is non-discretionary; parental consent is not required for the public health report.
— Occupational elevated BLL reportable to state-based Adult Blood Lead Epidemiology and Surveillance (ABLES) programs.
— Landlords of pre-1978 housing must disclose known lead hazards (Title X, 1992) and provide the EPA "Protect Your Family from Lead" pamphlet.
— Tenants with lead-poisoned children may have legal recourse; refer to legal aid/medical-legal partnerships — increasingly part of integrated pediatric care.
— Document housing conditions in the medical record — supports abatement orders and litigation if needed.
— Elevated BLL is not by itself grounds for a child protective services (CPS) report — most cases reflect environmental hazards, not neglect.
— CPS referral appropriate when caregivers refuse abatement, refuse chelation for severely elevated BLL, or fail to remove the child from a known ongoing exposure despite resources being provided.
— Engage social work and public health first; CPS as last resort.
— Discuss that chelation does not reverse neurodevelopmental damage already sustained; it reduces ongoing toxicity and future injury.
— Disclose adverse effects: nephrotoxicity, hypersensitivity, hemolysis (BAL/G6PD), zinc depletion.
— Verify G6PD status and peanut allergy before BAL.
— Lead exposure disproportionately affects Black, Hispanic, low-income, and immigrant children — a marker of structural inequity. Screening, abatement funding (HUD grants, Medicaid coverage), and follow-up should be actively coordinated; passive referral often fails.
— Move between providers, foster placement, or housing relocation often results in missed BLL retests. Build closed-loop tracking into EMR.
Board pearl: A parent refusing to allow her child to leave a known lead-contaminated home despite offered housing assistance and refusing chelation for BLL 75 µg/dL → after exhausting motivational interviewing, social work, and public health involvement, CPS referral is appropriate. This is a classic Step 3 ethics scenario.
— Cosmetics: kohl, surma, kajal, sindoor.
— Folk remedies: azarcón, greta, pay-loo-ah, ghasard.
— Spices: turmeric (adulterated for color), chili powder.
— Ceramics, pottery glazes, leaded crystal.
— Toys, jewelry, candy wrappers (especially imported from Mexico).
— DMSA = Daily oral, Documented BLL 45–69.
— EDTA = Emergent IV, ≥70.
— BAL = Brain (encephalopathy), give Before EDTA, Banned in G6PD.
Board pearl: If the stem includes "recent home renovation" or "lives in a pre-1978 house" plus any of microcytic anemia, developmental delay, abdominal pain, or seizures in a toddler — the answer involves BLL testing. Don't overthink it.
— 12-month well-child visit, Medicaid-enrolled, lives in 1940s apartment. Next step? → Capillary BLL screening per CMS mandate; confirm elevation with venous draw.
— 2-year-old with developmental concerns, Hgb 9.5, MCV 68, basophilic stippling, ferritin 12. → Check BLL (lead and IDA often coexist; treat both).
— 4-year-old, BLL 50 µg/dL, asymptomatic, lead-safe home arranged. Treatment? → Outpatient DMSA (succimer) 19-day course.
— 3-year-old with seizures, BLL 95 µg/dL, papilledema. → Admit ICU, BAL IM, then CaNa₂EDTA IV 4 hours later (NOT EDTA first).
— 35-year-old battery recycler, fatigue, HTN, BLL 55 µg/dL. → Remove from workplace (OSHA medical removal protection), monitor; chelate only if symptomatic or BLL ≥80.
— Plumber renovating old homes, develops wrist extensor weakness, microcytic anemia, BLL 85. → Lead neuropathy; chelation with DMSA + exposure removal.
— 28-week pregnant immigrant from Mexico, uses pottery for cooking, BLL 28 µg/dL. → Remove exposure, calcium 1500 mg/day, serial BLL; chelation not yet indicated.
— Toddler with elevated BLL, KUB shows opacity in stomach. → Whole-bowel irrigation with PEG before chelation.
— Parents refuse abatement, child has BLL 80 µg/dL, on third reactivation. → Engage social work, public health; if persistent refusal endangers child, CPS referral.
— Post-chelation BLL drops from 55 to 25, then 3 weeks later is 48. → Bone redistribution; repeat course if still ≥45.
— Retired painter with refractory gout, HTN, CKD, normal-sized kidneys. → Consider chronic lead nephropathy; check BLL +/- bone lead.
Key distinction: The differentiator on most stems is the specific BLL number and symptom status — memorize the thresholds (45 for outpatient DMSA, 70 for inpatient dual chelation, encephalopathy at any BLL → BAL+EDTA).
Lead poisoning has no safe blood level, demands exposure interruption before chelation, and is treated outpatient with oral DMSA at BLL 45–69 µg/dL in children, inpatient with BAL followed by CaNa₂EDTA for BLL ≥70 µg/dL or any encephalopathy — while the most important interventions are environmental abatement, public health reporting, iron repletion, and longitudinal neurodevelopmental and renal follow-up.
— Children: <45 = no chelation, education + abatement + nutrition; 45–69 = oral DMSA; ≥70 or symptomatic = BAL IM + CaNa₂EDTA IV (BAL first, EDTA 4 hr later).
— Adults: chelate if BLL ≥80 µg/dL or symptomatic ≥50; remove from workplace per OSHA at BLL 50/60.
— Encephalopathy at any BLL = BAL + EDTA, ICU.
Board pearl: When in doubt on a stem, the highest-yield next step is rarely "give another drug" — it's "identify and remove the source" plus "report to public health." That answer is correct more often than any chelator on the Step 3 exam.